A Phase 1/2 interventional study of BNT112 and Cemiplimab in Prostate Cancer, sponsored by BioNTech SE. Terminated at 22 sites in 4 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-20.
Sponsored by BioNTech SE · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 333 studies in Prostatic Neoplasms with a site in Germany — 71 open to participants now, 117 under way, 36 of them phase 3. Prostatic Neoplasms · Germany.
Among the 333 studies in Prostatic Neoplasms with a site in Germany, this one is the 220th largest by enrollment of the 269 interventional ones that give a count, is one of 19 that started in 2019, is one of 13 in phase 1/2, and was the 218th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →71 of the 333 studies in Prostatic Neoplasms with a site in Germany are open now. Recruiting first, the newest first:
University Hospital Tuebingen · Sites in Germany
Ages 18–80 · Men only
AstraZeneca · Sites in Germany, United States, Austria and 18 more countries
Ages 18+ · Men only
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD · Sites in Germany, France, Italy and 2 more countries
Ages 18+ · Men only
AstraZeneca · Sites in Germany, United States, Australia and 4 more countries
Ages 18–99 · Men only
Novartis Pharmaceuticals · Sites in Germany, United States, Australia and 5 more countries
Ages 18+ · Men only
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
333 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 71 · Phase 3 113 · Phase 4 9
First in 1995; this study’s year is marked. 19 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 75 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 278 across the 269 interventional studies, 461 across the 61 observational. Of the 199 that completed or were terminated, 93 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
217 of 333 have an industry lead sponsor. The 10 most frequent:
BioNTech SE is the lead sponsor of 76 studies on the registry; 25 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 26 (79%) have results posted.
BioNTech SE has 5 studies filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
27 of the studies in Prostatic Neoplasms with a site in Germany that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03767244Phase 3Janssen Research & Development, LLCA Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | 2026-12-01 |
| NCT06551324Phase 3PfizerA Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). | 2027-02-28 |
| NCT06122584Phase 3ABX advanced biochemical compounds GmbHDiagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer | 2027-03 |
| NCT02531516Phase 3Aragon Pharmaceuticals, Inc.An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS | 2027-03-01 |
| NCT05794906Phase 3BayerA Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies | 2027-07-30 |
Add all 27 to your calendar (.ics) → With an account.
Among the 333 studies in Prostatic Neoplasms with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Open-label, multicenter, dose titration and four-arm expansion trial to evaluate the safety, tolerability, immunogenicity, and preliminary efficacy of BNT112 cancer vaccine (BNT112) monotherapy or in combination with cemiplimab in patients with metastatic castration resistant prostate cancer (mCRPC: Part 1 and Part 2 Arms 1A and 1B) and in patients with high-risk, localized prostate cancer (LPC).
As of February 2023, the trial only recruited LPC patients and no longer mCRPC patients.
Inclusion criteria:
Specific key inclusion criteria for mCRPC patients (Part 1 and Part 2 Arms 1A and 1B) - Recruitment of mCRPC patients now completed:
Specific key inclusion criteria for newly diagnosed LPC patients (Part 2 Arms 2 and 3):
Treatment-naïve patients with LPC (i.e., N0, M0). According to risk levels of the European Association of Urology Guidelines on Prostate Cancer (2018), and in line with the U.S. National Comprehensive Cancer Network (NCCN 2020), patients had at least 1 of the following:
Main exclusion criteria for all patients:
Medical conditions
Patients who had a known history of any of the following:
Patients who have received or currently receive the following therapy/treatment:
Specific key exclusion criteria for mCRPC Patients (Part 1 and Part 2 Arms 1A and 1B) - Recruitment of mCRPC patients now completed:
Excluded medical conditions
Patients with clinically active .
Excluded prior or concomitant anti-cancer therapies
Patients who received or currently receive the following anti-cancer therapy/agent:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BNT112 monotherapy Enrollment into this arm is completed.
Biological: BNT112
BNT112 in combination with cemiplimab Enrollment into this arm is completed.
Biological: BNT112 · Drug: Cemiplimab
BNT112 monotherapy Enrollment into this arm is completed.
Biological: BNT112
BNT112 in combination with cemiplimab
Biological: BNT112 · Drug: Cemiplimab
BNT112 monotherapy
Biological: BNT112
Following progression after BNT112 monotherapy, patients in Arm 1b have the option to be treated with cemiplimab monotherapy Enrollment into this arm is completed.
Drug: Cemiplimab
Intravenous bolus injection
Intravenous infusion
Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)
DLT criteria were defined as following: any treatment-emergent adverse events (TEAE) of Grade 5 intensity; hematological toxicities (Grade 3 and 4 febrile neutropenia, Grade 4 thrombocytopenia, Grade 3 and 4 hemorrhage associated with thrombocytopenia of Grade greater than or equal to \[\>=\] 3, Grade 4 anemia); and non-hematological toxicities (Grade 4 cytokine release syndrome \[CRS\], Grade 3 CRS which has not improved to Grade 1 or resolved within 48 hours; any Grade \>=3 non-hematological TEAE at least possibly related which occurs during the first BNT112 cancer vaccine treatment cycle).
Time frame: Cycle 1 (21 days)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Related to Trial Procedure
TEAE: any adverse event (AE) with an onset date on or after the first administration of investigational medicinal product (IMP) or worsened after first administration of IMP. AEs with an onset date more than 30 days after last dose of BNT112 or 90 days after last dose of cemiplimab (for Part 2, Arm 1a and Arm 2) were only considered as TEAEs if assessed as related to IMP by the investigator. Serious adverse event (SAE): any untoward medical occurrence that, at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect or was another medically important condition. AEs were graded for severity using National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI-CTCAE v5.0), where Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4 - Life-threatening consequences; Grade 5: Death related to AE.
Time frame: From Baseline up to 30 days after the last dose of BNT112 (for Part 1 and Part 2 Arms 1b and 3) or up to 90 days after the last dose of cemiplimab (for Part 2, Arm 1a and Arm 2) (up to 4 years and 1 month)
Part 2 Arm 1a: Objective Response Rate (ORR)
ORR was defined as the percentage of participants with a complete response (CR) or partial response (PR) as per Prostate Cancer Working Group 3 (PCWG3) criteria as determined by the investigator. Participants not meeting the criteria for CR or PR, including those without any post-baseline tumor assessments, were considered as non-responders. CR was defined as the disappearance of all target lesions, with a reduction in short axis to \<10 mm in any pathological lymph nodes and no new lesions. PR was defined as 30% decrease in the sum of the longest diameter of target lesions.
Time frame: From start of treatment up to 46 weeks
Part 2 Arm 1b: Objective Response Rate (ORR)
ORR was defined as the percentage of participants with a CR or PR as per PCWG3 criteria as determined by the investigator. Participants not meeting the criteria for CR or PR, including those without any post-baseline tumor assessments, were considered as non-responders. CR was defined as the disappearance of all target lesions, with a reduction in short axis to \<10 mm in any pathological lymph nodes and no new lesions. PR was defined as 30% decrease in the sum of the longest diameter of target lesions.
Time frame: From start of treatment up to 104 weeks
Number of Participants Reporting Change From Baseline in Prostate-specific Antigen (PSA) Levels
Participants blood samples were tested for levels of PSA to track the progression of prostate cancer. PSA decline categories of No decline, 0 to 25%, \>25% to 50%, and \>50% compared to baseline during treatment according to PCWG3 (as reported by the investigator) are reported in this outcome measure. EOT in the timeframe below refers to End of treatment.
Time frame: Day8 (Cycles1&2 only), Day1 Cycle 2 & Day 15 (Cycles1,2 & 8 only) (each cycle of 21-days), & EOT (30 days after last dose of BNT112 [Part 1 & Part 2 Arms 1b & 3] or 90 days after last dose of cemiplimab [Part 2, Arm 1a & Arm 2] [up to 4 years & 1 months])
Number of Participants Reporting Change From Baseline in PSA Doubling Time (PSADT)
Participants blood samples were tested for levels of PSA to track the progression of prostate cancer. PSADT was calculated using a linear regression model of the natural logarithm of PSA values and time. PSA doubling time compared to baseline during the treatment period for the following categories: 0 - 3 months; \>3 - 6 months; \>6 - 9 months; \>9 - 12 months; \>12 - 18 months; \>18 - 24 months; \>24 months and declining are reported in this outcome measure.
Time frame: Cycle 4 Day 1, Cycle 8 Day 1, Cycle 12 Day 1 (each cycle duration=21 days)
Number of Participants With PSA Decline of >=50%
Participants blood samples were tested for levels of PSA to track the progression of prostate cancer. Participants with PSA decline of \>=50% compared to baseline according to PCWG3 (as reported by the investigator) are reported in this outcome measure. EOT in the timeframe below refers to End of treatment.
Time frame: Day8 (Cycles1&2 only), Day1 Cycle 2 & Day 15 (Cycles1,2 & 8 only) (each cycle of 21-days), & EOT (30 days after last dose of BNT112 [Part 1 & Part 2 Arms 1b & 3] or 90 days after last dose of cemiplimab [Part 2, Arm 1a & Arm 2] [up to 4 years & 1 months])
Part 1: Objective Response Rate (ORR)
ORR was defined as the percentage of participants with a CR or PR as per PCWG3 criteria as determined by the investigator. Participants not meeting the criteria for CR or PR, including those without any post-baseline tumor assessments, were considered as non-responders. CR was defined as the disappearance of all target lesions, with a reduction in short axis to \<10 mm in any pathological lymph nodes and no new lesions. PR was defined as 30% decrease in the sum of the longest diameter of target lesions.
Time frame: From start of treatment up to 27 weeks
Part 2: Arms 2 and 3: Number of Participants With Tumor Response Post-Treatment
The best overall response was defined as a single best response status at any tumor response assessment after first administration of IMP and prior to or at the start date of the first subsequent anti-cancer therapy. Overall response of progressive disease within 14 days after the start date of first subsequent anti-cancer therapy was considered. The following order of tumor response categories were used, where "Complete Response" is the best category: Complete Response (CR) - Partial Response (PR) - Stable Disease (SD) - Progressive Disease (PD) - Not Evaluable (NE) - Missing. CR: disappearance of all target lesions, with reduction in short axis to \<10 mm in any pathological lymph nodes and no new lesions. PR:30% decrease in the sum of the longest diameter of target lesions. PD: progression of target lesions (sum of diameter increase to nadir of \>=20% and by \>=5 mm), progression of existing non-target lesions, or appearance of 1 or more new lesions.SD: no evidence of PD, CR or PR.
Time frame: From start of treatment up to 25 weeks (Arm 2) and up to 26 weeks (Arm 3)
The trial consisted of 2 parts: Part 1 (dose titration) and Part 2 (dose expansion; consisted of four arms).
| Milestone | Part 1 (mCRPC): BNT112 | Part 2 (mCRPC): Arm 1a: BNT112 + Cemiplimab | Part 2 (mCRPC): Arm 1b: BNT112 | Part 2 (LPC): Arm 2: BNT112 + Cemiplimab | Part 2 (LPC): Arm 3: BNT112 |
|---|---|---|---|---|---|
| Started | 9 | 0 | 0 | 0 | 0 |
| Completed | 2 | 0 | 0 | 0 | 0 |
| Not completed | 7 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 6 | 0 | 0 | 0 | 0 |
| Milestone | Part 1 (mCRPC): BNT112 | Part 2 (mCRPC): Arm 1a: BNT112 + Cemiplimab | Part 2 (mCRPC): Arm 1b: BNT112 | Part 2 (LPC): Arm 2: BNT112 + Cemiplimab | Part 2 (LPC): Arm 3: BNT112 |
|---|---|---|---|---|---|
| Started | 0 | 28 | 27 | 5 | 6 |
| Completed | 0 | 10 | 9 | 4 | 5 |
| Not completed | 0 | 18 | 18 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Death | 0 | 17 | 13 | 1 | 0 |
| Withdrew: Progressive disease | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 1 | 1 | 0 | 1 |
| Withdrew: Other | 0 | 0 | 1 | 0 | 0 |
DLT criteria were defined as following: any treatment-emergent adverse events (TEAE) of Grade 5 intensity; hematological toxicities (Grade 3 and 4 febrile neutropenia, Grade 4 thrombocytopenia, Grade 3 and 4 hemorrhage associated with thrombocytopenia of Grade greater than or equal to \[\>=\] 3, Grade 4 anemia); and non-hematological toxicities (Grade 4 cytokine release syndrome \[CRS\], Grade 3 CRS which has not improved to Grade 1 or resolved within 48 hours; any Grade \>=3 non-hematological TEAE at least possibly related which occurs during the first BNT112 cancer vaccine treatment cycle).
| Participants | Part 1 (mCRPC): BNT112 |
|---|---|
| Part 1: Number of Participants With Dose Limiting Toxicities (DLTs) | 2 |
TEAE: any adverse event (AE) with an onset date on or after the first administration of investigational medicinal product (IMP) or worsened after first administration of IMP. AEs with an onset date more than 30 days after last dose of BNT112 or 90 days after last dose of cemiplimab (for Part 2, Arm 1a and Arm 2) were only considered as TEAEs if assessed as related to IMP by the investigator. Serious adverse event (SAE): any untoward medical occurrence that, at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect or was another medically important condition. AEs were graded for severity using National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI-CTCAE v5.0), where Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4 - Life-threatening consequences; Grade 5: Death related to AE.
| Participants | Part 1 (mCRPC): BNT112 | Part 2 (mCRPC): Arm 1a: BNT112 + Cemiplimab | Part 2 (mCRPC): Arm 1b: BNT112 | Part 2 (LPC): Arm 2: BNT112 + Cemiplimab | Part 2 (LPC): Arm 3: BNT112 |
|---|---|---|---|---|---|
| TEAEs | 8 | 28 | 26 | 5 | 6 |
| Serious TEAE | 5 | 5 | 9 | 2 | 2 |
| Grade >= 3 TEAEs | 7 | 15 | 15 | 1 | 4 |
| Grade 5 TEAEs | 2 | 0 | 1 | 0 | 0 |
| TEAEs related to trial procedure | 1 | 1 | 0 | 1 | 2 |
ORR was defined as the percentage of participants with a complete response (CR) or partial response (PR) as per Prostate Cancer Working Group 3 (PCWG3) criteria as determined by the investigator. Participants not meeting the criteria for CR or PR, including those without any post-baseline tumor assessments, were considered as non-responders. CR was defined as the disappearance of all target lesions, with a reduction in short axis to \<10 mm in any pathological lymph nodes and no new lesions. PR was defined as 30% decrease in the sum of the longest diameter of target lesions.
| percentage of participants | Part 2 (mCRPC): Arm 1a: BNT112 + Cemiplimab |
|---|---|
| Part 2 Arm 1a: Objective Response Rate (ORR) | 0 (0.0 to 12.8) |
Participants blood samples were tested for levels of PSA to track the progression of prostate cancer. PSA decline categories of No decline, 0 to 25%, \>25% to 50%, and \>50% compared to baseline during treatment according to PCWG3 (as reported by the investigator) are reported in this outcome measure. EOT in the timeframe below refers to End of treatment.
| Participants | Part 1 (mCRPC): BNT112 | Part 2 (mCRPC): Arm 1a: BNT112 + Cemiplimab | Part 2 (mCRPC): Arm 1b: BNT112 | Part 2 (LPC): Arm 2: BNT112 + Cemiplimab | Part 2 (LPC): Arm 3: BNT112 |
|---|---|---|---|---|---|
| Cycle 1 Day 8: No decline | — | — | — | — | 1 |
| Cycle 1 Day 8: 0 to 25% | — | — | — | — | 0 |
| Cycle 1 Day 8: Greater than (>) 25% to 50% | — | — | — | — | 0 |
| Cycle 1 Day 8: >50% | — | — | — | — | 0 |
| Cycle 1 Day 15: No decline | — | — | — | — | 0 |
| Cycle 1 Day 15: 0 to 25% | — | — | — | — | 0 |
| Cycle 1 Day 15: >25% to 50% | — | — | — | — | 1 |
| Cycle 1 Day 15: >50% | — | — | — | — | 0 |
| Cycle 2 Day 1: No decline | 6 | 21 | 19 | 1 | 0 |
| Cycle 2 Day 1: 0 to 25% | 2 | 3 | 2 | 1 | 1 |
| Cycle 2 Day 1: Greater than (>) 25% to 50% | 0 | 0 | 1 | 0 | 1 |
| Cycle 2 Day 1: >50% | 0 | 0 | 1 | 3 | 4 |
| Cycle 2 Day 8: No decline | 1 | — | — | — | 0 |
| Cycle 2 Day 8: 0 to 25% | 0 | — | — | — | 0 |
| Cycle 2 Day 8: > 25% to 50% | 0 | — | — | — | 0 |
| Cycle 2 Day 8: >50% | 0 | — | — | — | 1 |
| Cycle 2 Day 15: No decline | — | — | — | — | 0 |
| Cycle 2 Day 15: 0 to 25% | — | — | — | — | 0 |
| Cycle 2 Day 15: > 25% to 50% | — | — | — | — | 0 |
| Cycle 2 Day 15: >50% | — | — | — | — | 1 |
| Cycle 8 Day 15: No decline | — | — | 1 | — | — |
| Cycle 8 Day 15: 0 to 25% | — | — | 0 | — | — |
| Cycle 8 Day 15: > 25% to 50% | — | — | 0 | — | — |
| Cycle 8 Day 15: >50% | — | — | 0 | — | — |
| EOT: No decline | 7 | 17 | 19 | 0 | 0 |
| EOT: 0 to 25% | 0 | 2 | 0 | 0 | 0 |
| EOT: > 25% to 50% | 0 | 0 | 0 | 0 | 0 |
| EOT: >50% | 0 | 0 | 0 | 4 | 3 |
Participants blood samples were tested for levels of PSA to track the progression of prostate cancer. PSADT was calculated using a linear regression model of the natural logarithm of PSA values and time. PSA doubling time compared to baseline during the treatment period for the following categories: 0 - 3 months; \>3 - 6 months; \>6 - 9 months; \>9 - 12 months; \>12 - 18 months; \>18 - 24 months; \>24 months and declining are reported in this outcome measure.
| Participants | Part 1 (mCRPC): BNT112 | Part 2 (mCRPC): Arm 1a: BNT112 + Cemiplimab | Part 2 (mCRPC): Arm 1b: BNT112 | Part 2 (LPC): Arm 2: BNT112 + Cemiplimab | Part 2 (LPC): Arm 3: BNT112 |
|---|---|---|---|---|---|
| Cycle 4 Day 1: 0 - 3 months | 5 | 16 | 11 | 1 | 0 |
| Cycle 4 Day 1: >3 - 6 months | 0 | 2 | 2 | 0 | 0 |
| Cycle 4 Day 1: >6 - 9 months | 1 | 1 | 2 | 0 | 0 |
| Cycle 4 Day 1: >9 - 12 months | 0 | 0 | 0 | 0 | 0 |
| Cycle 4 Day 1: >12 - 18 months | 0 | 0 | 0 | 0 | 0 |
| Cycle 4 Day 1: >18 - 24 months | 0 | 0 | 1 | 0 | 0 |
| Cycle 4 Day 1: >24 months | 0 | 0 | 0 | 0 | 0 |
| Cycle 4 Day 1: Declining | 0 | 2 | 3 | 4 | 5 |
| Cycle 8 Day 1: 0 - 3 months | 3 | 6 | 8 | 0 | 0 |
| Cycle 8 Day 1: >3 - 6 months | 0 | 5 | 1 | 0 | 0 |
| Cycle 8 Day 1: >6 - 9 months | 0 | 1 | 0 | 0 | 0 |
| Cycle 8 Day 1: >9 - 12 months | 0 | 0 | 2 | 0 | 0 |
| Cycle 8 Day 1: >12 - 18 months | 0 | 0 | 1 | 0 | 0 |
| Cycle 8 Day 1: >18 - 24 months | 0 | 0 | 0 | 0 | 0 |
| Cycle 8 Day 1: > 24 months | 1 | 0 | 1 | 0 | 0 |
| Cycle 8 Day 1: Declining | 0 | 1 | 2 | 5 | 6 |
| Cycle 12 Day 1: 0 - 3 months | 3 | 2 | 0 | 0 | 0 |
| Cycle 12 Day 1: >3 - 6 months | 0 | 3 | 1 | 0 | 0 |
| Cycle 12 Day 1: >6 - 9 months | 0 | 1 | 2 | 0 | 0 |
| Cycle 12 Day 1: >9 - 12 months | 0 | 0 | 1 | 0 | 0 |
| Cycle 12 Day 1: >12 - 18 months | 0 | 0 | 0 | 0 | 0 |
| Cycle 12 Day 1: >18 - 24 months | 0 | 0 | 0 | 0 | 0 |
| Cycle 12 Day 1: > 24 months | 0 | 0 | 0 | 0 | 0 |
| Cycle 12 Day 1: Declining | 0 | 1 | 2 | 4 | 3 |
Participants blood samples were tested for levels of PSA to track the progression of prostate cancer. Participants with PSA decline of \>=50% compared to baseline according to PCWG3 (as reported by the investigator) are reported in this outcome measure. EOT in the timeframe below refers to End of treatment.
| Participants | Part 1 (mCRPC): BNT112 | Part 2 (mCRPC): Arm 1a: BNT112 + Cemiplimab | Part 2 (mCRPC): Arm 1b: BNT112 | Part 2 (LPC): Arm 2: BNT112 + Cemiplimab | Part 2 (LPC): Arm 3: BNT112 |
|---|---|---|---|---|---|
| Cycle 1 Day 8 | — | — | — | — | 0 |
| Cycle 1 Day 15 | — | — | — | — | 0 |
| Cycle 2 Day 1 | 0 | 0 | 1 | 3 | 4 |
| Cycle 2 Day 8 | 0 | — | — | — | 1 |
| Cycle 2 Day 15 | — | — | — | — | 1 |
| Cycle 8 Day 15 | — | — | 0 | — | — |
| EOT | 0 | 0 | 0 | 4 | 3 |
ORR was defined as the percentage of participants with a CR or PR as per PCWG3 criteria as determined by the investigator. Participants not meeting the criteria for CR or PR, including those without any post-baseline tumor assessments, were considered as non-responders. CR was defined as the disappearance of all target lesions, with a reduction in short axis to \<10 mm in any pathological lymph nodes and no new lesions. PR was defined as 30% decrease in the sum of the longest diameter of target lesions.
| percentage of participants | Part 1 (mCRPC): BNT112 |
|---|---|
| Part 1: Objective Response Rate (ORR) | 0 (0.0 to 33.6) |
The best overall response was defined as a single best response status at any tumor response assessment after first administration of IMP and prior to or at the start date of the first subsequent anti-cancer therapy. Overall response of progressive disease within 14 days after the start date of first subsequent anti-cancer therapy was considered. The following order of tumor response categories were used, where "Complete Response" is the best category: Complete Response (CR) - Partial Response (PR) - Stable Disease (SD) - Progressive Disease (PD) - Not Evaluable (NE) - Missing. CR: disappearance of all target lesions, with reduction in short axis to \<10 mm in any pathological lymph nodes and no new lesions. PR:30% decrease in the sum of the longest diameter of target lesions. PD: progression of target lesions (sum of diameter increase to nadir of \>=20% and by \>=5 mm), progression of existing non-target lesions, or appearance of 1 or more new lesions.SD: no evidence of PD, CR or PR.
| Participants | Part 2 (LPC): Arm 2: BNT112 + Cemiplimab | Part 2 (LPC): Arm 3: BNT112 |
|---|---|---|
| Complete Response (CR) | 0 | 0 |
| Partial Response (PR) | 3 | 3 |
| Stable Disease (SD) | 2 | 2 |
| Progressive Disease (PD) | 0 | 0 |
| Not Evaluable (NE) | 0 | 0 |
| Missing | 0 | 1 |
ORR was defined as the percentage of participants with a CR or PR as per PCWG3 criteria as determined by the investigator. Participants not meeting the criteria for CR or PR, including those without any post-baseline tumor assessments, were considered as non-responders. CR was defined as the disappearance of all target lesions, with a reduction in short axis to \<10 mm in any pathological lymph nodes and no new lesions. PR was defined as 30% decrease in the sum of the longest diameter of target lesions.
| percentage of participants | Part 2 (mCRPC): Arm 1b: BNT112 |
|---|---|
| Part 2 Arm 1b: Objective Response Rate (ORR) | 12.0 (2.5 to 31.2) |
Collected over From Baseline up to 30 days after the last dose of BNT112 (for Part 1 and Part 2 Arm 1b and 3) or up to 90 days after the last dose of cemiplimab (for Part 2, Arm 1a and Arm 2) (up to 4 years and 1 month). As per the protocol, non-SAEs with an onset date more than 30 days after the last dose of BNT112 or 90 days after the last dose of cemiplimab (for Part 2, Arm 1a and Arm 2) are only reported below if assessed as related to IMP by the investigator.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1 (mCRPC): BNT112 | 7/9 (77.8%) | 5/9 (55.6%) | 8/9 (88.9%) |
| Part 2 (mCRPC): Arm 1a: BNT112 + Cemiplimab | 17/28 (60.7%) | 5/28 (17.9%) | 28/28 (100%) |
| Part 2 (mCRPC): Arm 1b: BNT112 | 13/27 (48.1%) | 9/27 (33.3%) | 26/27 (96.3%) |
| Part 2 (LPC): Arm 2: BNT112 + Cemiplimab | 1/5 (20%) | 2/5 (40%) | 5/5 (100%) |
| Part 2 (LPC): Arm 3: BNT112 | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| Event | Part 1 (mCRPC): BNT112 | Part 2 (mCRPC): Arm 1a: BNT112 + Cemiplimab | Part 2 (mCRPC): Arm 1b: BNT112 | Part 2 (LPC): Arm 2: BNT112 + Cemiplimab | Part 2 (LPC): Arm 3: BNT112 |
|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 2/9 | 1/28 | 0/27 | 0/5 | 0/6 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/9 | 0/28 | 0/27 | 0/5 | 0/6 |
| IleusGastrointestinal disorders | 0/9 | 0/28 | 0/27 | 1/5 | 1/6 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 0/9 | 0/28 | 0/27 | 1/5 | 0/6 |
| TinnitusEar and labyrinth disorders | 0/9 | 0/28 | 0/27 | 0/5 | 1/6 |
| ParaesthesiaNervous system disorders | 0/9 | 0/28 | 0/27 | 0/5 | 1/6 |
| HypertensionVascular disorders | 0/9 | 0/28 | 0/27 | 0/5 | 1/6 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/9 | 0/28 | 0/27 | 0/5 | 0/6 |
| Abdominal painGastrointestinal disorders | 1/9 | 0/28 | 0/27 | 0/5 | 0/6 |
| NauseaGastrointestinal disorders | 1/9 | 0/28 | 0/27 | 0/5 | 0/6 |
| Event | Part 1 (mCRPC): BNT112 | Part 2 (mCRPC): Arm 1a: BNT112 + Cemiplimab | Part 2 (mCRPC): Arm 1b: BNT112 | Part 2 (LPC): Arm 2: BNT112 + Cemiplimab | Part 2 (LPC): Arm 3: BNT112 |
|---|---|---|---|---|---|
| ChillsGeneral disorders | 1/9 | 16/28 | 6/27 | 1/5 | 4/6 |
| PyrexiaGeneral disorders | 6/9 | 17/28 | 16/27 | 1/5 | 2/6 |
| Influenza like illnessGeneral disorders | 2/9 | 5/28 | 5/27 | 3/5 | 2/6 |
| HypertensionVascular disorders | 4/9 | 4/28 | 5/27 | 1/5 | 3/6 |
| AnaemiaBlood and lymphatic system disorders | 4/9 | 8/28 | 4/27 | 0/5 | 0/6 |
| NauseaGastrointestinal disorders | 4/9 | 6/28 | 6/27 | 1/5 | 1/6 |
| HeadacheNervous system disorders | 1/9 | 3/28 | 2/27 | 2/5 | 2/6 |
| Urinary incontinenceRenal and urinary disorders | 0/9 | 1/28 | 0/27 | 2/5 | 0/6 |
| FatigueGeneral disorders | 2/9 | 10/28 | 5/27 | 1/5 | 2/6 |
| DiarrhoeaGastrointestinal disorders | 1/9 | 2/28 | 6/27 | 0/5 | 2/6 |
Analysis was performed on Intent to Treat (ITT) population that included all participants who were randomized to the investigational medicinal product (IMP).
| Age, Customized(Participants) | Part 1 (mCRPC): BNT112 | Part 2 (mCRPC): Arm 1a: BNT112 + Cemiplimab | Part 2 (mCRPC): Arm 1b: BNT112 | Part 2 (LPC): Arm 2: BNT112 + Cemiplimab | Part 2 (LPC): Arm 3: BNT112 | Total |
|---|---|---|---|---|---|---|
| < 50 years | 0 | 0 | 0 | 0 | 0 | 0 |
| >= 50 - < 65 years | 1 | 7 | 11 | 3 | 4 | 26 |
| >= 65 - < 85 years | 8 | 20 | 16 | 2 | 2 | 48 |
| >= 85 years | 0 | 1 | 0 | 0 | 0 | 1 |
| Sex: Female, Male(Participants) | Part 1 (mCRPC): BNT112 | Part 2 (mCRPC): Arm 1a: BNT112 + Cemiplimab | Part 2 (mCRPC): Arm 1b: BNT112 | Part 2 (LPC): Arm 2: BNT112 + Cemiplimab | Part 2 (LPC): Arm 3: BNT112 | Total |
|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 9 | 28 | 27 | 5 | 6 | 75 |
| Ethnicity (NIH/OMB)(Participants) | Part 1 (mCRPC): BNT112 | Part 2 (mCRPC): Arm 1a: BNT112 + Cemiplimab | Part 2 (mCRPC): Arm 1b: BNT112 | Part 2 (LPC): Arm 2: BNT112 + Cemiplimab | Part 2 (LPC): Arm 3: BNT112 | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 4 | 0 | 0 | 0 | 4 |
| Not Hispanic or Latino | 9 | 23 | 27 | 4 | 6 | 69 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 | 0 | 2 |
| Race (NIH/OMB)(Participants) | Part 1 (mCRPC): BNT112 | Part 2 (mCRPC): Arm 1a: BNT112 + Cemiplimab | Part 2 (mCRPC): Arm 1b: BNT112 | Part 2 (LPC): Arm 2: BNT112 + Cemiplimab | Part 2 (LPC): Arm 3: BNT112 | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 | 2 | 1 | 5 |
| White | 8 | 27 | 26 | 3 | 5 | 69 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2019 to primary completion in Jan 2024, 49 months.
Results were first posted in Mar 2025, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cemiplimab